Former Chief Medical Officer · Keros Therapeutics, Inc. (KROS)

Simon Cooper

A named executive officer of Keros Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,760,775

Salary $116,099Stock awards $0

FY2023: $2,245,597

5th of 5 named executive officers at Keros Therapeutics by FY2024 total.

5 named officers on file for Keros Therapeutics, FY2024

Simon Cooper’s pay file — $29

  • 3 fiscal years of pay, line by line
  • KROS’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Keros Therapeutics’s whole pay program stands against its peers

  • Keros Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KROS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2025 (DEF 14A).

Free

Get Simon Cooper’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Simon Cooper compensation by year

Keros Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Keros Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$464,423$469,808$116,099
Bonus$0$0$0
Stock awards$0$0$0
Option awards$1,659,196$1,561,306$1,633,436
Non-equity incentive$184,000$206,800$0
Pension and deferred compensation$0$0$0
All other$5,848$7,683$11,240
Total$2,313,467$2,245,597$1,760,775

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Keros Therapeutics, Inc. DEF 14A filed April 23, 2025, accession 0001104659-25-037982, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Keros Therapeutics, Inc. filed document, accession 0001104659-25-037982. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.

$2.3M
$2.2M
$1.8M
FY22
FY23
FY24
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option26,250—$34.98
Option40,000—$54.38
Option28,125—$46.30

Per the Outstanding Equity Awards at Fiscal Year-End table in Keros Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Keros Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Christopher RovaldiPresident and Chief Operating Officer$6,975,416
Jasbir SeehraChief Executive Officer and Chair$6,273,192
Yung ChyungChief Medical Officer$5,641,367
Keith RegnanteChief Financial Officer$2,292,177
Simon Cooper · this pageFormer Chief Medical Officer$1,760,775

The full Keros Therapeutics compensation record

free company brief

This page is one person within Keros Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Keros Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Simon Cooper's compensation dossier · One-time report. No refunds.